Shares of GlaxoSmithKline PLC (NYSE:GSK) gapped up prior to trading on Monday . The stock had previously closed at $42.41, but opened at $42.98. GlaxoSmithKline PLC shares last traded at $44.26, with a volume of 3,915,200 shares trading hands.

Several equities analysts have recently weighed in on the stock. Zacks Investment Research raised shares of GlaxoSmithKline PLC from a “sell” rating to a “hold” rating in a research report on Monday, July 25th. Citigroup Inc. reissued a “buy” rating on shares of GlaxoSmithKline PLC in a research report on Wednesday, August 10th. Beaufort Securities reissued a “buy” rating on shares of GlaxoSmithKline PLC in a research report on Tuesday, August 2nd. Jefferies Group raised shares of GlaxoSmithKline PLC from a “hold” rating to a “buy” rating in a research report on Thursday, July 14th. Finally, Argus increased their price objective on shares of GlaxoSmithKline PLC from $48.00 to $50.00 and gave the company a “buy” rating in a research report on Friday, August 12th. One research analyst has rated the stock with a sell rating, twelve have assigned a hold rating, eight have issued a buy rating and one has given a strong buy rating to the company. GlaxoSmithKline PLC presently has an average rating of “Hold” and an average target price of $47.19.

The firm’s 50 day moving average price is $44.26 and its 200-day moving average price is $42.20. The company has a market cap of $107.57 billion and a P/E ratio of 2766.25.

The business also recently declared a dividend, which will be paid on Thursday, October 13th. Investors of record on Friday, August 12th will be issued a $0.494 dividend. The ex-dividend date is Wednesday, August 10th.

A hedge fund recently raised its stake in GlaxoSmithKline PLC stock. BlackRock Advisors LLC increased its position in GlaxoSmithKline PLC (NYSE:GSK) by 2,368.8% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 345,182 shares of the pharmaceutical company’s stock after buying an additional 331,200 shares during the period. BlackRock Advisors LLC’s holdings in GlaxoSmithKline PLC were worth $13,928,000 at the end of the most recent quarter.

GlaxoSmithKline plc (GSK) is a healthcare company. The Company is engaged in the creation and discovery, development, manufacture and marketing of pharmaceutical products, including vaccines, over-the-counter (OTC) medicines and health-related consumer products. The Company’s segments include Pharmaceuticals, Pharmaceuticals R&D, Vaccines and Consumer Healthcare.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.